Clinically relevant genetic variations in drug metabolizing enzymes

Current Drug Metabolism

Volumn 12, Issue 5, 2011, Pages 487-497

  Pinto, Navin ^a,b   Dolan, M Eileen ^a,b  

^a Section of Hematology/Oncology   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adverse drug reactions; Cytochrome P450; Drug metabolizing enzymes; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphisms

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DRUG METABOLIZING ENZYME; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERFORIN; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; NELFINAVIR; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRASUGREL; RIFAMPICIN; RITONAVIR; TAMOXIFEN; UNINDEXED DRUG; WARFARIN;

ARTICLE; DRUG EFFICACY; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; METABOLITE; PHARMACOGENETICS;

BIOMARKERS, PHARMACOLOGICAL; DRUG LABELING; DRUG THERAPY; GENETIC VARIATION; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955685734     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795495321     Document Type: Article

References (146)

1. Motulsky, A. G. Drug reactions enzymes, and biochemical genetics. J. Am. Med. Assoc., 1957, 165, 835-837.
2. Vogel, F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd, 1959, 12, 52-125.
3. Goodman, L. S., Gilman, A., Brunton, L. L., Lazo, J. S. & Parker, K. Goodman & Gilman's the pharmacological basis of therapeutics. 11th edn; McGraw-Hill, 2006.
4. Conney, A. H.; Miller, E. C.; Miller, J. A. Substrate-induced synthesis and other properties of benzpyrene hydroxylase in rat liver. J. Biol. Chem., 1957, 228, 753-766.
5. Brodie, B. B.; Gillette, J. R.; La Du, B.N. Enzymatic metabolism of drugs and other foreign compounds. Annu. Rev. Biochem., 1958, 27, 427-454.
6. Omura, T.; Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem., 1962, 237, 1375-1376.
7. Cooper, D. Y.; Estabrook, R. W.; Rosenthal, O. The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. J. Biol. Chem., 1963, 238, 1320-1323.
8. Cooper, D. Y.; Levin, S.; Narasimhulu, S.; Rosenthal, O. Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems. Science, 1965, 147, 400-402.
9. Sladek, N. E.; Mannering, G. J. Induction of drug metabolism. II. Qualitative differences in the microsomal N-demethylating systems stimulated by polycyclic hydrocarbons and by phenobarbital. Mol. Pharmacol., 1969, 5, 186-199.
10. Sladek, N. E.; Mannering, G. J. Induction of drug metabolism. I. Differences in the mechanisms by which polycyclic hydrocarbons and phenobarbital produce their inductive effects on microsomal Ndemethylating systems. Mol. Pharmacol., 1969, 5, 174-185.
11. Wiebel, F. J.; Selkirk, J. K.; Gelboin, H. V.; Haugen, D. A.; van der Hoeven, T. A.; Coon, M. J. Position-specific oxygenation of benzo(a)pyrene by different forms of purified cytochrome P-450 from rabbit liver. Proc. Natl. Acad. Sci. U S A, 1975, 72, 3917-3920.
12. Schenkman, J. B.; Jansson, I.; Backes, W. L.; Cheng, K. C.; Smith, C. Dissection of cytochrome P-450 isozymes (RLM) from fractions of untreated rat liver microsomal proteins. Biochem. Biophys. Res. Commun., 1982, 107, 1517-1523. (Pubitemid 13222444)
13. Nebert, D. W.; Nelson, D. R.; Coon, M. J.; Estabrook, R. W.; Feyereisen, R.; Fujii-Kuriyama, Y.; Gonzalez, F. J.; Guengerich, F. P.; Gunsalus, I. C.; Johnson, E. F.; & et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol., 1991, 10, 1-14.
14. Nebert, D. W.; Adesnik, M.; Coon, M. J.; Estabrook, R. W.; Gonzalez, F. J.; Guengerich, F. P.; Gunsalus, I. C.; Johnson, E. F.; Kemper, B.; Levin, W. & et al. The P450 gene superfamily: recommended nomenclature. DNA, 1987, 6, 1-11. (Pubitemid 17033547)
15. Robarge, J. D.; Li, L.; Desta, Z.; Nguyen, A.; Flockhart, D. A. The star-allele nomenclature: retooling for translational genomics. Clin. Pharmacol. Ther., 2007, 82, 244-248. (Pubitemid 47258470)
16. Lawton, M. P.; Cashman, J. R.; Cresteil, T.; Dolphin, C. T.; Elfarra, A. A.; Hines, R. N.; Hodgson, E.; Kimura, T.; Ozols, J.; Phillips, I. R. & et al. A nomenclature for the mammalian flavincontaining monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys., 1994, 308, 254-257. (Pubitemid 24172630)
17. Duester, G.; Farres, J.; Felder, M.R.; Holmes, R. S.; Hoog, J. O.; Pares, X.; Plapp, B. V.; Yin, S. J.; Jornvall, H. Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family. Biochem. Pharmacol., 1999, 58, 389-395.
18. Maguire, J. J.; Parker, W. A.; Foord, S. M.; Bonner, T. I.; Neubig, R. R.; Davenport, A.P. International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol. Rev., 2009, 61, 1-8.
19. Black, W. J.; Stagos, D.; Marchitti, S. A.; Nebert, D. W.; Tipton, K. F.; Bairoch, A.; Vasiliou, V. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet. Genomics, 2009, 19, 893-902.
20. Mackenzie, P. I.; Bock, K. W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J. O.; Owens, I. S.; Nebert, D.W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics., 2005, 15, 677-685. (Pubitemid 41345319)
21. Hein, D.W.; Boukouvala, S.; Grant, D.M.; Minchin, R.F.; Sim, E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet. Genomics, 2008, 18, 367-368. (Pubitemid 351367530)
22. Mahgoub, A.; Idle, J. R.; Dring, L.G.; Lancaster, R.; Smith, R.L. Polymorphic hydroxylation of Debrisoquine in man. Lancet, 1977, 2, 584-586. (Pubitemid 8176607)
23. Eichelbaum, M.; Spannbrucker, N.; Steincke, B.; Dengler, H.J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 1979, 16, 183-187. (Pubitemid 10194487)
24. Evans, D. A.; Mahgoub, A.; Sloan, T. P.; Idle, J. R.; Smith, R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet., 1980, 17, 102-105. (Pubitemid 10107632)
25. Bertilsson, L.; Dengler, H.J.; Eichelbaum, M.; Schulz, H.U. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur. J. Clin. Pharmacol., 1980, 17, 153-155. (Pubitemid 10149749)
26. Bertilsson, L.; Eichelbaum, M.; Mellstrom, B.; Sawe, J.; Schulz, H. U. Sjoqvist, F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci., 1980, 27, 1673-1677. (Pubitemid 11220225)
27. Hammer, W.; Sjoqvist, F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci., 1967, 6, 1895-1903.
28. Alexanderson, B.; Evans, D. A.; Sjoqvist, F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br. Med. J., 1969, 4, 764-768.
29. Heim, M.; Meyer, U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 1990, 336, 529-532. (Pubitemid 20278099)
30. Gough, A. C.; Miles, J. S.; Spurr, N. K.; Moss, J. E.; Gaedigk, A.; Eichelbaum, M.; Wolf, C. R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 1990, 347, 773-776.
31. Gaedigk, A.; Blum, M.; Gaedigk, R.; Eichelbaum, M.; Meyer, U.A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet., 1991, 48, 943-950. (Pubitemid 21891638)
32. Hanioka, N.; Kimura, S.; Meyer, U. A.; Gonzalez, F. J. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am. J. Hum. Genet., 1990, 47, 994-1001. (Pubitemid 120024070)
33. Johansson, I.; Lundqvist, E.; Bertilsson, L.; Dahl, M. L.; Sjoqvist, F.; Ingelman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U S A., 1993, 90, 11825-11829. (Pubitemid 24008732)
34. Ingelman-Sundberg, M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol., 2005, 207, 52-56.
35. Chinta, S. J.; Pai, H.V.; Upadhya, S.C.; Boyd, M.R.; Ravindranath, V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res., 2002, 103, 49-61. (Pubitemid 34775033)
36. Prueksaritanont, T.; Dwyer, L. M.; Cribb, A. E. (+)-bufuralol 1'- hydroxylation activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol, 1995, 50, 1521-1525.
37. Guidice, J. M.; Marez, D.; Sabbagh, N.; Legrand-Andreoletti, M.; Spire, C.; Alcaide, E.; Lafitte, J. J.; Broly, F. Evidence for CYP2D6 expression in human lung. Biochem. Biophys. Res. Commun., 1997, 241, 79-85. (Pubitemid 28033542)
38. Ingelman-Sundberg, M.; Sim, S. C.; Gomez, A.; Rodriguez- Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 2007, 116, 496-526. (Pubitemid 350116943)
39. Boullata, J. I.; Armenti, V. T. Handbook of drug-nutrient interactions. Humana Press, 2004.
40. Man, M.; Farmen, M.; Dumaual, C.; Teng, C. H.; Moser, B.; Irie, S.; Noh, G. J.; Njau, R.; Close, S.; Wise, S.; Hockett, R. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharmacol., 2010, 50, 929-940.
41. Rudorfer, M.V.; Lane, E. A.; Potter, W. Z. Interethnic dissociation between debrisoquine and desipramine hydroxylation. J. Clin. Psychopharmacol., 1985, 5, 89-92. (Pubitemid 15149498)
42. Zhan, M.; Flaws, J. A.; Gallicchio, L.; Tkaczuk, K.; Lewis, L. M.; Royak-Schaler, R. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect. Prev., 2007, 31, 384-390. (Pubitemid 350166794)
43. Caraco, Y.; Sheller, J.; Wood, A.J. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther., 1999, 290, 413-422. (Pubitemid 29302351)
44. Wu, X.; Hawse, J. R.; Subramaniam, M.; Goetz, M. P.; Ingle, J. N.; Spelsberg, T. C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res., 2009, 69, 1722-1727.
45. Goetz, M. P.; Rae, J. M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Flockhart, D. A.; Desta, Z.; Perez, E. A.; Ingle, J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 2005, 23, 9312-9318.
46. Rae, J. M.; Goetz, M. P.; Hayes, D. F.; Ingle, J. N.; Li, L.; Storniolo, A. M.; Stearns, V.; Flockhart, D. A. CYP2D6 genotype and tamoxifen response. Breast Cancer Res., 2005, 7, E6.
47. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K. H.; Skaar, T.; Storniolo, A. M.; Li, L.; Araba, A.; Blanchard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilboum, R. M.; Rae, J. M.; Hayes, D. F.; Flockhart, D. A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 2005, 97, 30-39.
48. Schroth, W.; Goetz, M. P.; Hamann, U.; Fasching, P. A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V. J.; Ames, M. M.; Safgren, S. L.; Kuffel, M. J.; Ulmer, H. U.; Bolander, J.; Strick, R.; Beckmann, M. W.; Koelbl, H.; Weinshilboum, R. M.; Ingle, J. N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 2009, 302, 1429-1436.
49. Schroth, W.; Hamann, U.; Fasching, P. A.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res., 2010, 16, 4468-4477.
50. Stearns, V.; Johnson, M. D.; Rae, J. M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D.F.; Desta, Z.; Flockhart, D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst., 2003, 95, 1758-1764. (Pubitemid 38008898)
51. Dezentje, V.O.; van Blijderveen, N.J.; Gelderblom, H.; Putter, H.; van Herk-Sukel, M. P.; Casparie, M. K.; Egberts, A.C.; Nortier, J.W.; Guchelaar, H.J. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol., 2010, 28, 2423-2429.
52. Madadi, P.; Koren, G.; Cairns, J.; Chitayat, D.; Gaedigk, A.; Leeder, J. S.; Teitelbaum, R.; Karaskov, T.; Aleksa, K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can. Fam. Physician, 2007, 53, 33-35. (Pubitemid 46166581)
53. Madadi, P.; Ross, C. J.; Hayden, M. R.; Carleton, B. C.; Gaedigk, A.; Leeder, J. S.; Koren, G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther., 2009, 85, 31-35.
54. Sapeika, N. The excretion of drugs in human milk; a review. J. Obstet. Gynaecol. Br. Emp., 1947, 54, 426-431.
55. Findlay, J.W.; DeAngelis, R.L.; Kearney, M.F.; Welch, R.M.; Findlay, J.M. Analgesic drugs in breast milk and plasma. Clin. Pharmacol. Ther., 1981, 29, 625-633. (Pubitemid 11039302)
56. Meny, R.G.; Naumburg, E.G.; Alger, L.S.; Brill-Miller, J.L.; Brown, S. Codeine and the breastfed neonate. J. Hum. Lact., 1993, 9, 237-240.
57. Kupfer, A.; Preisig, R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol., 1984, 26, 753-759. (Pubitemid 14074652)
58. de Morais, S. M.; Wilkinson, G. R.; Blaisdell, J.; Nakamura, K.; Meyer, U. A.; Goldstein, J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 1994, 269, 15419-15422.
59. Flockhart, D. A. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin. Pharmacokinet., 1995, 29 Suppl 1, 45-52.
60. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee
61. Desta, Z.; Zhao, X.; Shin, J. G.; Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet., 2002, 41, 913-958. (Pubitemid 35168437)
62. Levy, R. H. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia, 1995, 36 Suppl 5, S8-13.
63. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Meneveau, N.; Steg, P.G.; Ferrieres, J.; Danchin, N.; Becquemont, L. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360, 363-375.
64. Shuldiner, A. R.; O'Connell, J. R.; Bliden, K. P.; Gandhi, A.; Ryan, K., Horenstein, R. B.; Damcott, C. M.; Pakyz, R.; Tantry, U. S.; Gibson, Q.; Pollin, T. I.; Post, W.; Parsa, A.; Mitchell, B. D.; Faraday, N.; Herzog, W.; Gurbel, P. A. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009, 302, 849-857.
65. Ellis, K. J.; Stouffer, G. A.; McLeod, H. L.; Lee, C. R. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics, 2009, 10, 1799-1817.
66. Sofi, F.; Giusti, B.; Marcucci, R.; Gori, A. M.; Abbate, R.; Gensini, G. F. Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a metaanalysis. Pharmacogenomics J., 2010.
67. Sibbing, D.; Koch, W.; Gebhard, D.; Schuster, T.; Braun, S.; Stegherr, J.; Morath, T.; Schomig, A.; von Beckerath, N. Kastrati, A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 2010, 121, 512-518.
68. Geisler, T.; Schaeffeler, E.; Dippon, J.; Winter, S.; Buse, V.; Bischofs, C.; Zuern, C.; Moerike, K.; Gawaz, M.; Schwab, M. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 2008, 9, 1251-1259.
69. Sorich, M. J.; Vitry, A.; Ward, M. B.; Horowitz, J. D.; McKinnon, R. A. Prasugrel vs. clopidogrel for cytochrome P450 2C19- genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost., 2010, 8, 1678-1684.
70. Fontana, P.; Senouf, D.; Mach, F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res., 2008, 121, 463-468. (Pubitemid 351174278)
71. Bouman, H. J.; Schomig, E.; van Werkum, J. W.; Velder, J.; Hackeng, C. M.; Hirschhauser, C.; Waldmann, C.,; Schmalz, H. G.; ten Berg, J. M.; Taubert, D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med., 2011, 17, 110-116.
72. Aithal, G. P.; Day, C. P.; Kesteven, P. J.; Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353, 717-719. (Pubitemid 29103806)
73. Xie, H. G.; Prasad, H. C.; Kim, R. B.; Stein, C. M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 2002, 54, 1257-1270. (Pubitemid 35284252)
74. Scott, S. A.; Jaremko, M.; Lubitz, S. A.; Kornreich, R.; Halperin, J. L.; Desnick, R. J. CYP2C9*8 is prevalent among African- Americans: implications for pharmacogenetic dosing. Pharmacogenomics, 2009, 10, 1243-1255.
75. Cavallari, L. H.; Langaee, T. Y.; Momary, K. M.; Shapiro, N. L.; Nutescu, E. A.; Coty, W. A.; Viana, M. A.; Patel, S. R.; Johnson, J. A. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther., 2010, 87, 459-464.
76. Black, D.J.; Kunze, K.L.; Wienkers, L.C.; Gidal, B.E.; Seaton, T.L.; McDonnell, N.D.; Evans, J. S.; Bauwens, J. E.; Trager, W. F. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos., 1996, 24, 422-428.
77. Klein, T. E.; Altman, R. B.; Eriksson, N.; Gage, B. F.; Kimmel, S. E.; Lee, M. T.; Limdi, N. A.; Page, D.; Roden, D. M.; Wagner, M. J.; Caldwell, M. D.; Johnson, J. A. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 2009, 360, 753-764.
78. Joo, J.; Geller, N. L.; French, B.; Kimmel, S.E.; Rosenberg, Y.; Ellenberg, J.H. Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial. Clin. Trials, 2010, 7, 597-604.
79. Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT,
80. Kim, M. J.; Huang, S. M.; Meyer, U. A.; Rahman, A.; Lesko, L. J. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol., 2009, 49, 138-146.
81. Kato, M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab. Pharmacokinet., 2008, 23, 87-94.
82. Daly, A. K. Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet., 2006, 45, 13-31. (Pubitemid 43145013)
83. Lamba, J. K.; Lin, Y. S.; Schuetz, E. G.; Thummel, K. E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev., 2002, 54, 1271-1294. (Pubitemid 35284253)
84. Roy, P.; Waxman, D. J. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol. In Vitro, 2006, 20, 176-186. (Pubitemid 43087701)
85. Rotger, M.; Tegude, H.; Colombo, S.; Cavassini, M.; Furrer, H.; Decosterd, L.; Blievernicht, J.; Saussele, T.; Gunthard, H. F.; Schwab, M.; Eichelbaum, M.; Telenti, A.; Zanger, U. M. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther., 2007, 81, 557-566. (Pubitemid 46454205)
86. Benowitz, N. L.; Swan, G. E.; Jacob, P.; 3rd, Lessov-Schlaggar, C. N. & Tyndale, R. F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther., 2006, 80, 457-467. (Pubitemid 44767882)
87. Mwenifumbo, J. C.; Tyndale, R. F. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics, 2007, 8, 1385-1402. (Pubitemid 350162852)
88. Ho, M. K.; Mwenifumbo, J. C.; Al Koudsi, N.; Okuyemi, K. S.; Ahluwalia, J. S.; Benowitz, N. L.; Tyndale, R. F. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther., 2009, 85, 635-643.
89. Thorgeirsson, T. E.; Gudbjartsson, D. F.; Surakka, I.; Vink, J. M.; Amin, N.; Geller, F.; Sulem, P.; Rafnar, T.; Esko, T.; Walter, S.; Gieger, C.; Rawal, R.; Mangino, M.; Prokopenko, I.; Magi, R.; Keskitalo, K.; Gudjonsdottir, I. H.; Gretarsdottir, S.; Stefansson, H.; Thompson, J. R.; Aulchenko, Y. S.; Nelis, M.; Aben, K. K.; den Heijer, M.; Dirksen, A.; Ashraf, H.; Soranzo, N.; Valdes, A. M.; Steves, C.; Uitterlinden, A. G.; Hofman, A.; Tonjes, A.; Kovacs, P.; Hottenga, J. J.; Willemsen, G.; Vogelzangs, N.; Doring, A.; Dahmen, N.; Nitz, B.; Pergadia, M. L.; Saez, B.; De Diego, V.; Lezcano, V.; Garcia-Prats, M. D.; Ripatti, S.; Perola, M.; Kettunen, J.; Hartikainen, A. L.; Pouta, A.; Laitinen, J.; Isohanni, M.; Huei- Yi, S.; Allen, M.; Krestyaninova, M.; Hall, A. S.; Jones, G. T.; van Rij, A. M.; Mueller, T.; Dieplinger, B.; Haltmayer, M.; Jonsson, S.; Matthiasson, S. E.; Oskarsson, H.; Tyrfingsson, T.; Kiemeney, L. A.; Mayordomo, J. I.; Lindholt, J. S.; Pedersen, J. H.; Franklin, W. A.; Wolf, H.; Montgomery, G. W.; Heath, A. C.; Martin, N. G.; Madden, P. A.; Giegling, I.; Rujescu, D.; Jarvelin, M. R.; Salomaa, V.; Stumvoll, M.; Spector, T. D.; Wichmann, H. E.; Metspalu, A.; Samani, N. J.; Penninx, B. W.; Oostra, B. A.; Boomsma, D. I.; Tiemeier, H.; van Duijn C. M.; Kaprio, J.; Gulcher, J. R.; McCarthy, M. I.; Peltonen, L.; Thorsteinsdottir, U.; Stefansson, K. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet., 2010, 42, 448-453.
90. Bohanec Grabar, P.; Rozman, B.; Tomsic, M.; Suput, D.; Logar, D.; Dolzan, V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol., 2008, 64, 871-876.
91. Hockwald, R. S.; Arnold, J.; Clayman, C. B.; Alving, A. S. Toxicity of primaquine in Negroes. J. Am. Med. Assoc., 1952, 149, 1568-1570.
92. Clayman, C. B.; Arnold, J.; Hockwald, R. S.; Yount, E. H.; Jr., Edgcomb, J. H.; Alving, A. S. Toxicity of primaquine in Caucasians. J. Am. Med. Assoc., 1952, 149, 1563-1568.
93. Alving, A. S.; Carson, P. E.; Flanagan, C. L.; Ickes, C. E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science, 1956, 124, 484-485.
94. Hirono, A.; Beutler, E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc. Natl. Acad. Sci. U S A, 1988, 85, 3951-3954.
95. Town, M.; Bautista, J. M.; Mason, P. J.; Luzzatto, L. Both mutations in G6PD A- are necessary to produce the G6PD deficient phenotype. Hum. Mol. Genet., 1992, 1, 171-174.
96. Vives-Corrons, J. L.; Kuhl, W.; Pujades, M. A.; Beutler, E. Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A. Am. J. Hum. Genet., 1990, 47, 575-579.
97. van Kuilenburg, A. B.; De Abreu, R. A.; van Gennip, A. H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem., 2003, 40, 41-45. (Pubitemid 36051408)
98. van Kuilenburg, A. B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer, 2004, 40, 939-950. (Pubitemid 38496249)
99. Etienne, M. C.; Lagrange, J. L.; Dassonville, O.; Fleming, R.; Thyss, A.; Renee, N.; Schneider, M.; Demard, F.; Milano, G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 1994, 12, 2248-2253. (Pubitemid 24346691)
100. Lu, Z.; Zhang, R.; Carpenter, J. T.; Diasio, R. B. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res., 1998, 4, 325-329. (Pubitemid 28122745)
101. Ogura, K.; Ohnuma, T.; Minamide, Y.; Mizuno, A.; Nishiyama, T.; Nagashima, S.; Kanamaru, M.; Hiratsuka, A.; Watabe, T.; Uematsu, T. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin. Cancer Res., 2005, 11, 5104-5111. (Pubitemid 41003694)
102. Morsman, J. M.; Sludden, J.; Ameyaw, M. M.; Githang, A. J.; Indalo, A.; Ofori-Adjei, D.; McLeod, H. L. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br. J. Clin. Pharmacol., 2000, 50, 269-272.
103. Saif, M. W.; Mattison, L.; Carollo, T.; Ezzeldin, H.; Diasio, R. B.; Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother. Pharmacol., 2006, 58, 396-401. (Pubitemid 43800744)
104. Van Kuilenburg, A. B.; Vreken, P.; Abeling, N. G.; Bakker, H. D.; Meinsma, R.; Van Lenthe, H.; De Abreu, R. A.; Smeitink, J. A.; Kayserili, H.; Apak, M. Y.; Christensen, E.; Holopainen, I.; Pulkki, K.; Riva, D.; Botteon, G.; Holme, E.; Tulinius, M.; Kleijer, W. J.; Beemer, F. A.; Duran, M.; Niezen-Koning, K. E.; Smit, G. P.; Jakobs, C.; Smit, L. M.; Van Gennip, A. H.; et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet, 1999, 104, 1-9. (Pubitemid 29134634)
105. Yen, J. L.; McLeod, H. L. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer, 2007, 43, 1011-1016. (Pubitemid 46483039)
106. Johnson, M. R.; Yan, J.; Shao, L.; Albin, N.; Diasio, R. B. Semiautomated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J. Chromatogr. B. Biomed. Sci. Appl., 1997, 696, 183-191. (Pubitemid 27387445)
107. Ciccolini, J.; Mercier, C.; Evrard, A.; Dahan, L.; Boyer, J. C.; Duffaud, F.; Richard, K.; Blanquicett, C.; Milano, G.; Blesius, A.; Durand, A.; Seitz, J. F.; Favre, R.; Lacarelle, B. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit., 2006, 28, 678-685. (Pubitemid 44564069)
108. Mattison, L. K.; Ezzeldin, H.; Carpenter, M.; Modak, A.; Johnson, M. R.; Diasio, R. B. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin. Cancer Res., 2004, 10, 2652-2658. (Pubitemid 38509138)
109. Yang, C. G.; Ciccolini, J.; Blesius, A.; Dahan, L.; Bagarry-Liegey, D.; Brunet, C.; Varoquaux, A.; Frances, N.; Marouani, H.; Giovanni, A.; Ferri-Dessens, R. M.; Chefrour, M.; Favre, R.; Duffaud, F.; Seitz, J. F.; Zanaret, M.; Lacarelle, B.; Mercier, C. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother. Pharmacol., 2010.
110. Koukouritaki, S. B.; Hines, R. N. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics, 2005, 6, 807-822. (Pubitemid 41724355)
111. Peng, G. S.; Yin, S. J. Effect of the allelic variants of aldehyde dehydrogenase ALDH2*2 and alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations. Hum. Genomics, 2009, 3, 121-127.
112. Edenberg, H. J. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health, 2007, 30, 5-13.
113. Fan, M.; Liu, B.; Jiang, T.; Jiang, X.; Zhao, H.; Zhang, J. Metaanalysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr. Genet., 2010, 20, 1-7.
114. Devadatta, S.; Gangadharam, P. R.; Andrews, R. H.; Fox, W.; Ramakrishnan, C. V.; Selkon, J. B.; Velu, S. Peripheral neuritis due to isoniazid. Bull World Health Organ, 1960, 23, 587-598.
115. Hughes, H. B.; Biehl, J. P.; Jones, A. P.; Schmidt, L. H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am. Rev. Tuberc., 1954, 70, 266-273.
116. Evans, D. A.; Manley, K. A.; Mc, K. V. Genetic control of isoniazid metabolism in man. Br. Med. J., 1960, 2, 485-491.
117. Harris, H. W.; Knight, R. A.; Selin, M. J. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am. Rev. Tuberc., 1958, 78, 944-948.
118. Blum, M.; Demierre, A.; Grant, D. M.; Heim, M.; Meyer, U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. U S A, 1991, 88, 5237-5241. (Pubitemid 21914719)
119. Vatsis, K. P.; Martell, K. J.; Weber, W. W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. U S A, 1991, 88, 6333-6337. (Pubitemid 21914940)
120. Hickman, D.; Sim, E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol., 1991, 42, 1007-1014.
121. Hitchings, G. H.; Elion, G. B.; Falco, E. A.; Russell, P. B.; Vanderwerff, H. Studies on analogs of purines and pyrimidines. Ann. N. Y. Acad. Sci., 1950, 52, 1318-1335.
122. Weinshilboum, R. M.; Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet., 1980, 32, 651-662. (Pubitemid 10061685)
123. Lennard, L.; Van Loon, J. A.; Lilleyman, J. S.; Weinshilboum, R. M. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther., 1987, 41, 18-25. (Pubitemid 17008125)
124. Szumlanski, C.; Otterness, D.; Her, C.; Lee, D.; Brandriff, B.; Kelsell, D.; Spurr, N.; Lennard, L.; Wieben, E.; Weinshilboum, R. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol., 1996, 15, 17-30. (Pubitemid 26029354)
125. Tai, H. L.; Krynetski, E. Y.; Yates, C. R.; Loennechen, T.; Fessing, M. Y.; Krynetskaia, N. F.; Evans, W. E. Thiopurine Smethyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet., 1996, 58, 694-702. (Pubitemid 26086658)
126. Otterness, D.; Szumlanski, C.; Lennard, L.; Klemetsdal, B.; Aarbakke, J.; Park-Hah, J. O.; Iven, H.; Schmiegelow, K.; Branum, E.; O'Brien, J.; Weinshilboum, R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther., 1997, 62, 60-73. (Pubitemid 27327100)
127. Teml, A.; Schaeffeler, E.; Herrlinger, K. R.; Klotz, U.; Schwab, M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet., 2007, 46, 187-208. (Pubitemid 46425646)
128. Karas-Kuzelicki, N.; Mlinaric-Rascan, I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics, 2009, 10, 1309-1322.
129. Relling, M. V.; Gardner, E. E.; Sandborn, W. J.; Schmiegelow, K.; Pui, C. H.; Yee, S. W.; Stein, C. M.; Carrillo, M.; Evans, W. E.; Klein, T. E. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing. Clin. Pharmacol. Ther., 2011.
130. Macklon, A. F.; Savage, R. L.; Rawlins, M. D. Gilbert's syndrome and drug metabolism. Clin. Pharmacokinet., 1979, 4, 223-232.
131. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R.; Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 1996, 347, 578-581. (Pubitemid 26070740)
132. Iyer, L.; King, C. D.; Whitington, P. F.; Green, M. D.; Roy, S. K.; Tephly, T. R.; Coffman, B. L.; Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 1998, 101, 847-854. (Pubitemid 28096082)
133. Ando, Y.; Fujita, K.; Sasaki, Y.; Hasegawa, Y. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr. Opin. Mol. Ther., 2007, 9, 258-262. (Pubitemid 46944317)
134. Jada, S. R.; Lim, R.; Wong, C. I.; Shu, X.; Lee, S. C.; Zhou, Q.; Goh, B. C.; Chowbay, B. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci;, 2007, 98, 1461-1467. (Pubitemid 47241771)
135. Onoue, M.; Terada, T.; Kobayashi, M.; Katsura, T.; Matsumoto, S.; Yanagihara, K.; Nishimura, T.; Kanai, M.; Teramukai, S.; Shimizu, A.; Fukushima, M.; Inui, K. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol., 2009, 14, 136-142.
136. Wadelius, M.; Chen, L. Y.; Downes, K.; Ghori, J.; Hunt, S.; Eriksson, N.; Wallerman, O.; Melhus, H.; Wadelius, C.; Bentley, D.; Deloukas, P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J., 2005, 5, 262-270. (Pubitemid 41131718)
137. Rettie, A. E.; Tai, G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol. Interv., 2006, 6, 223-227. (Pubitemid 44455204)
138. Takeuchi, F.; McGinnis, R.; Bourgeois, S.; Barnes, C.; Eriksson, N.; Soranzo, N.; Whittaker, P.; Ranganath, V.; Kumanduri, V.; McLaren, W.; Holm, L.; Lindh, J.; Rane, A.; Wadelius, M.; Deloukas, P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 2009, 5, e1000433.
139. Duan, S.; Huang, R. S.; Zhang, W.; Bleibel, W. K.; Roe, C. A.; Clark, T. A.; Chen, T. X.; Schweitzer, A. C.; Blume, J. E.; Cox, N. J.; Dolan, M. E. Genetic architecture of transcript-level variation in humans. Am. J. Hum. Genet., 2008, 82, 1101-1113.
140. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116, 281-297.
141. Shomron, N. MicroRNAs and pharmacogenomics. Pharmacogenomics, 2010, 11, 629-632.
142. Pennisi, E. Genomics. 1000 Genomes Project gives new map of genetic diversity. Science, 2010, 330, 574-575.
143. Daly, A. K.; Day, C. P. Genetic association studies in druginduced liver injury. Semin. Liver Dis., 2009, 29, 400-411.
144. Alfirevic, A.; Pirmohamed, M. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Pharmacogenomics, 2010, 11, 497-499.
145. Nishio, Y.; Makiyama, T.; Itoh, H.; Sakaguchi, T.; Ohno, S.; Gong, Y. Z.; Yamamoto, S.; Ozawa, T.; Ding, W. G.; Toyoda, F.; Kawamura, M.; Akao, M.; Matsuura, H.; Kimura, T.; Kita, T.; Horie, M. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J. Am. Coll. Cardiol., 2009, 54, 812-819.
146. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48, 689-723.